![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in its share price early this year. However, the tolerability data raised questions about the strength of Novo’s hand.
The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the Danish drugmaker can improve on the data that triggered a jump in its share price early this year. However, the tolerability data raised questions about the strength of Novo’s hand.
